New York, NY (PRWEB) April 15, 2014
The Tisch MS Research Center of New York (Tisch MSRCNY) today announced that they surpassed their campaign goal on Indiegogo.com to raise funds for their FDA-Approved Phase I Clinical Stem Cell Trial. The funding will be directly applied to the study and stem cell research at Tisch MSRCNY.
The target of $300K was met and surpassed within the allotted four weeks of the campaign's launch raising a total amount of $317,540. “We are overwhelmed and grateful for the generosity shown by our community of patients and friends,” stated Dr. Saud A. Sadiq, Chief Research Scientist at Tisch MSRCNY and the study’s principal investigator. He added, “Funding is like oxygen for research. Without financial support, our research into regenerative therapy cannot survive.”
As a non-profit,Tisch MS Research Center chose Indiegogo as a perfect platform since it has not received federal, state, or corporate funding to cover costs of this study. The crowd sourcing website heightened awareness and introduced new philanthropists to the Center’s mission to repair the damage caused by multiple sclerosis.
“The show of support has been tremendous, but our work is not done,” said David Greenstein, Chairman of the Board of Directors at Tisch MSRCNY. “We need the success of this campaign to jump start a steady stream of donations into the research center.”
For more information on this study and to make a donation, visit: http://www.tischms.org
ABOUT TISCH MS RESEARCH CENTER OF NEW YORK
For over twenty years, Dr. Saud A. Sadiq has believed that combining excellence in clinical care with innovative research targeted at finding the cure for multiple sclerosis would set an exemplary standard in the treatment of MS patients. Today, the Tisch MS Research Center of New York embodies this new model of healthcare, in which your doctor is also your researcher. Dr. Sadiq helps those with MS by conducting cutting-edge, patient-based research to ensure unparalleled care. The close relationship of the non-profit research center and its affiliated clinical practice (International Multiple Sclerosis Management Practice) enables the testing of new MS treatments and accelerates the pace at which research discoveries move from lab bench to bedside. The Tisch MS Research Center of New York aims to identify the disease trigger, optimize treatments for patients, and repair the damage caused by multiple sclerosis.